1. Introduction {#sec1}
===============

Type 2 diabetes (T2DM) is a major risk factor for the development of cardiovascular diseases (CVDs) \[[@B1]\]. It is estimated that, in the next 20 years, sub-Saharan Africa will have the highest growth in the number of people with diabetes among all other regions of the world, and this will increase the CVD burden \[[@B2], [@B3]\]. Traditional risk factors that predict CVD events fail to account for the excess CVD mortality found in T2DM patients. A number of studies have identified abnormalities of arterial function in diabetes patients \[[@B4]--[@B7]\], and it is now recognized that aortic stiffness, measured by pulse wave velocity (PWV), is highly predictive of cardiovascular and all-cause mortality in subjects with type 2 diabetes and general population, possibly across all age range \[[@B8]\].

Assessment of arterial stiffness in T2DM patients using pulse wave velocity (PWV) is often confounded by coexistent hypertension and blood pressure variations at the time of measurement. In both diabetes and nondiabetes subjects, PWV is strongly associated with age and blood pressure (BP) \[[@B4]\]. However, in sub-Saharan African population, contrary to Caucasians, BP accounts for higher variation of PWV than chronological age \[[@B9]\]. Cardioankle vascular index (CAVI) is a measure of arterial stiffness, reported to be less dependent on BP \[[@B10]\] and computed using two stiffness indices: *β*-stiffness and Bramwell-Hill\'s formula \[[@B11]\]. The high prevalence of hypertension in T2DM patients makes the contribution of diabetes*per se* to arterial stiffness difficult to ascertain. In this study, we compared the levels of arterial stiffness in nonhypertensive, nonobese T2DM patients to age- and gender-matched nondiabetes controls. We hypothesize that, compared to age- and gender-match controls, nonhypertensive, nonobese T2DM patients would have higher levels of arterial stiffness.

2. Methods {#sec2}
==========

2.1. Design and Subjects {#sec2.1}
------------------------

The study was conducted at the National Diabetes Management and Research Centre, Korle-Bu Teaching Hospital, Accra, Ghana. A total of 166 nonhypertensive, nonobese volunteers, comprising 96 T2DM patients and age- and gender-matched 86 nondiabetes controls within the ages of 35--75 years, were recruited for the study. T2DM was assessed clinically; the patients were diagnosed with diabetes after 30 years of age and treated initially with lifestyle management or oral hypoglycaemic drugs for at least 2 years. T2DM patients were selected by systematic sampling as every 4th consenting patient visiting the clinic. Based on the gender and age decade of T2DM patients, nondiabetes controls were randomly recruited from the surrounding communities into the study. All the nondiabetes volunteers were screened using fasting plasma glucose (FPG) and 2-hour post-75 g glucose load plasma glucose (2 h PPG) to confirm their nondiabetes status. In all, 95 nondiabetes, nonobese volunteers with no history of hypertension were enrolled into the study. However, 9 participants were excluded from analysis; 6 had impaired fasting glucose and 3 were impaired glucose tolerant (too few to be analysed!). Individuals with foot ulcers, established CVDs, BMI ≥ 30 kg/m^2^, history of hypertension treatment, and/or brachial blood pressure \>140/90 mmHg were excluded from the study. Ethical approval for this study was given by the University of Ghana Medical School Ethical and Protocol Review Committee (Protocol ID number MS-Et/M.2, P.4.10/2012-2013).

2.2. Anthropometric Measurements {#sec2.2}
--------------------------------

Using standard protocols \[[@B12]\], body weight was determined twice using a homologated electronic scale (Seca 770, Hamburg, Germany) following due calibration (precision ± 0.1 kg), with the patient wearing light clothing and shoes removed. Height was also measured with a portable system (Seca 222, Hamburg, Germany) with the patient shoeless in the upright position. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m^2^). Waist circumference was measured with nonelastic tape measure at the upper border of the iliac crest, parallel to the floor without compressing the skin. Body composition monitor (BF-508, Omron Healthcare, Inc., Vernon Hills, IL, USA) was used to assess percentage body.

2.3. Biochemical Analysis {#sec2.3}
-------------------------

Blood samples were drawn in the morning, after 8--12 hours of overnight fasting, into plain vacuum tubes to measure plasma lipids and fluoride oxalate tubes for glucose levels. FPG, 2 h PPG, total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, and triglyceride (TG) levels were analysed by colorimetric enzymatic assays using BS 120 chemical autoanalyzer (Mindray, China) and commercial reagents (Randox Laboratory Reagents, UK). Low-density lipoprotein cholesterol levels were calculated using Friedewald\'s formula \[[@B13]\]. HbA1c was assayed using affinity chromatography on PDQ Plus HPLC autoanalyzer (Primus Diagnostics, Trinity Biotech, Ireland). All analyses were performed at the Diabetes Research and Chronic Disease Reference Laboratory.

2.4. TensioMed Arteriograph Measurements {#sec2.4}
----------------------------------------

Arteriograph (TensioMed Kft., Hungary) was used to measure aortic pressure indices, aortic PWV (PWVao), and aortic augmentation index (AIx), with the subject lying supine for at least 10 minutes in a temperature controlled room (22 ± 2°C). The Arteriograph cuff was applied on the right arm over the brachial artery to detect arterial wall oscillations in the upper arm using the "stop-flow" principle previously described \[[@B14]\]. To determine aortic PWV, the Arteriograph uses the physiological behaviour of the wave reflection; the ejected direct (first systolic) pulse wave is reflected back mostly from the aortic bifurcation. The device measures the time interval between the peaks of the direct (first) and reflected (late) systolic wave (return time). For both the invasive and noninvasive aortic PWV computations, the aortic length is measured as distance from sternal notch (jugulum) to the upper edge of the pubic bone (symphysis). Stiffer arteries are less elastic and transmit pulse waves faster, reflected earlier at the abdominal aortic bifurcation, resulting in decreased pulse return time and, hence, higher PWV \[[@B15], [@B16]\]. To avoid overestimation of aortic path length by body surface contortions, a specialized body caliper was used to measure jugulum-symphysis distance.

PWVao was calculated by using the formula: $$\begin{matrix}
{\text{PWVao }\left( { m/s} \right) = \frac{2 \cdot \left( {jugulum\text{-symphysis  distance}} \right)}{\text{Return  time}}.} \\
\end{matrix}$$Augmentation index (AIx) is computed using the following algorithm:$$\begin{matrix}
{AIx = \frac{P_{2} - P_{1}}{PP} \times 100,} \\
\end{matrix}$$where *P* ~1~ is the amplitude of the first (direct) wave, *P* ~2~ is the amplitude of the late (reflected) systolic wave, and PP is the pulse pressure.

2.5. Vasera Measurements {#sec2.5}
------------------------

CAVI and heart-ankle (ha) PWV were measured using the Vasera 1500 N (Fukuda-Denshi, Japan) with the participant resting supine for at least 10 minutes before the measurement. Electrocardiogram electrodes were placed on both wrists, a microphone for detecting heart sounds was placed on the sternum, and cuffs were wrapped around the upper arms and the ankles. CAVI values were computed automatically. Briefly, CAVI corresponds to the stiffness parameter *β*, calculated from values of haPWV and BP as follows:$$\begin{matrix}
{\beta = \left( {\frac{2\rho}{\Delta P}} \right) \cdot \left\lbrack {{\ln\left\lbrack {\frac{P_{s}}{P_{d}}} \right\rbrack}} \right\rbrack \cdot {PWV}^{2},} \\
\end{matrix}$$where *ρ* indicates blood density; Δ*P* pulse pressure; ln natural log; *P* ~*s*~ systolic BP; and *P* ~*d*~ diastolic BP \[[@B11], [@B17]\].

CAVI and Arteriograph measurements were performed in random order using a digital algorithm.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Continuous data were analysed with the Shapiro-Wilk test to determine their distribution. Skewed data were logarithmically transformed. The data were presented as mean ± standard deviation and analysed by Student\'s *t*-test. Categorical data were presented as counts (percentages) analysed by the *χ* ^2^ test. Multiple regression analysis was performed with PWVao and CAVI, as well as haPWV and AIx, as the dependent variable, and the following parameters were forced into the model as covariates: diabetes status, age, gender, duration of diabetes (for T2DM patients group), BMI, height, previous smoking status, alcohol intake, systolic BP, heart rate, HbA1c, total cholesterol, triglycerides, and HDL cholesterol. *p* values \< 0.05 were considered statistically significant.

3. Results {#sec3}
==========

T2DM patients and nondiabetes controls were similar in age, gender distribution, lifestyle (alcohol and previous smoking status), and anthropometric indices. Mean values of AIx and peripheral and central BP indices measured by the Arteriograph were similar between T2DM patients and nondiabetes controls. However, diastolic and pulse BPs measured with Vasera were higher in nondiabetes controls than T2DM patient. Compared to nondiabetes controls, T2DM patients had higher PWVao and CAVI ([Table 1](#tab1){ref-type="table"}). When the study participants were categorised based on BMI, overweight participants (BMI = 25--30 kg/m^2^, *n* = 94) had higher CAVI but similar PWVao and haPWV, when compared to normal participants (BMI ≤ 24.9, *n* = 72; [Figure 1](#fig1){ref-type="fig"}). Also, based on BP, prehypertensive (BP = 130--139 mmHg, *n* = 78) participants had higher PWVao than nonhypertensive participants (BP \< 130 mmHg, *n* = 88; [Figure 2](#fig2){ref-type="fig"}).

In correlational analysis, PWVao increases with increasing age (*r* = 0.33; *p* = 0.005), body fat (*r* = 0.26; *p* = 0.028), brachial systolic pressure (*r* = 0.25; *p* = 0.034), and heart rate (*r* = 0.28; *p* = 0.018). No association was found between PWVao and duration of diabetes (*r* = 0.23; *p* = 0.055), BMI (*r* = 0.13; *p* = 0.272), and waist circumference (*r* = 0.21; *p* = 0.086). CAVI was found to be positively associated with age (*r* = 0.64; *p* \< 0.001) and duration of diabetes (*r* = 0.24; *p* = 0.041) but negatively associated with BMI (*r* = −0.26, *p* = 0.025). CAVI did not show any significant association with the components of brachial blood pressure parameters.

In the multiple regression analysis, determinants of PWVao in the entire study population were diabetes status, age, gender, systolic BP, and previous smoking status; in T2DM patients, they were age, duration of diabetes, gender, systolic BP, alcohol intake, and previous smoking status; in nondiabetes controls, they were age and gender. The determinants of CAVI in entire study population were diabetes status, age, BMI, heart rate, HbA1c, total cholesterol, and HDL cholesterol; in T2DM patients, they were age, duration of diabetes, and total cholesterol; in nondiabetes controls, they were age, WHR, systolic BP, heart rate, HDL cholesterol, and previous smoking status ([Table 2](#tab2){ref-type="table"}). Significant predictors of haPWV in the entire study population were age, gender, BMI, WHR, heart rate, HbA1c, total cholesterol, HDL cholesterol, and alcohol intake; in T2DM patients, they were age, duration of diabetes, gender, WHR, systolic BP, heart rate, HbA1c, and alcohol intake; in nondiabetes controls, they were age, HbA1c, total cholesterol, HDL cholesterol, and alcohol intake. Significant determinants for haPWV in the entire study population were age, gender, BMI, WHR, heart rate, HbA1c, total cholesterol, HDL cholesterol, and alcohol intake; in T2DM patients, they were age, duration of diabetes, gender, WHR, systolic BP, heart rate, HbA1c, and alcohol intake; and in nondiabetes controls, they were age, HbA1c, total cholesterol, HDL cholesterol, and alcohol intake. Significant predictors of AIx in the entire study population were diabetes status, age, gender, body height, systolic BP, heart rate, and HbA1c; in the T2DM patients, they were body height, systolic BP, heart rate, HbA1c, and HDL cholesterol; and in nondiabetes controls, they were age, WHR, body height, HDL cholesterol, and alcohol intake ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

This study provides data on arterial stiffness in nonhypertensive, nonobese indigenous black Africans with T2DM. In this gender and age matched cohort of comparable anthropometric, brachial, and aortic BP indices, we observed increased PWVao and CAVI in T2DM patients compared to nondiabetes controls. The differences in PWVao and CAVI between T2DM patients and nondiabetes controls persisted after multiple adjustments of various risk factors in regression models. The major finding of this study is that T2DM patients have increased stiffness in the arterial wall in the absence of systemic hypertension.

Diabetes is recognized as important risk factor for early arterial aging \[[@B8]\]. Previous studies have shown that T2DM stiffens the aorta and carotid, brachial, femoral, and lower-leg arteries \[[@B5], [@B6]\]. Our findings are similar to other studies. Compared to healthy controls, arterial stiffness was reported to be higher in T2DM patients in United Kingdom \[[@B4], [@B18]\]. In the Hoorn study, T2DM patients had increased arterial stiffness, measured ultrasonically as distensibility and compliance, of both elastic (carotid) and muscular (femoral and brachial) arteries \[[@B19]\]. Tedesco et al. also reported synergistic effect of hypertension and T2DM on arterial stiffness, measured as carotid-femoral PWV \[[@B20]\]. In Brazilian population studies \[[@B21]\], PWV was higher in diabetes patients than nondiabetes control when stratified by hypertension status.

It is well established that increased arterial stiffness is responsible for the earlier wave reflections and changes in pressure contours, leading to the elevation of peripheral and central systolic pressures and pulse pressure \[[@B22], [@B23]\]. In this study, however, compared to the nondiabetes controls, PWVao and CAVI were elevated in the T2DM subjects without accompanying increase in brachial and aortic BPs. This observation may indicate that, in T2DM, arterial stiffening precedes BP increase. The short mean duration of diabetes may imply that, at early phase of T2DM, aortic stiffness occurs without any appreciable increase in peripheral and central pressure indices. Insulin resistance and hyperglycaemia associated with T2DM may explain the increased arterial wall hypertrophy and fibrosis \[[@B24]\] through generation of advanced glycated end products \[[@B25]\], oxidative radicals \[[@B26]\], and proinflammatory cytokines \[[@B27]\]. These findings might be in agreement with the observation that people with T2DM have a 3- to 6-fold increased risk of CVDs compared to the general population and, also, the failure of traditional cardiovascular risk factors to account for the excess CVD risk in these patients \[[@B9], [@B22]\]. Large arterial stiffness has been demonstrated to be a cardiovascular risk factor in diabetes patients and people impaired glucose tolerance \[[@B4], [@B28]\]. The major determinants of PWV and CAVI in our study population are similar to what has been published in other studies \[[@B4], [@B5], [@B29]\].

In our study, mean AIx was similar among T2DM patients and nondiabetes controls; however, AIx was related to diabetes status after multiple adjustments of several risk factors in the regression model. Other studies have reported that AIx, which was similar between diabetes and nondiabetes subjects, increased in diabetes patients after adjustment of heart rate \[[@B29]--[@B32]\]. However, in one study, which included patients with T1DM and T2DM, no changes in AIx between patients and controls were observed after adjustment of heart rate \[[@B5]\]. AIx measures the arterial function, including wall stiffness, the number and location of reflection sites, and the amplitude and timing of the reflected wave. The inverse relationship between body height and AIx supports the previous findings that people with short stature have reduced distance to arterial pressure reflecting sites and this influences the timing and magnitude of arterial wave travel, causing early return to the heart (during systole) and resulting in an increase in AIx \[[@B30]\]. Short stature is independently associated with CVD mortality in longitudinal studies \[[@B34], [@B35]\] and meta-analysis \[[@B36]\].

In this study, novel equipment, the Arteriograph, was used to measure aortic stiffness. The principle of operation of the Arteriograph had been thoroughly investigated with invasive and noninvasive methods and has been found to be the measure of the stiffness of the central aorta in diabetes patients \[[@B37]\] and nondiabetes subjects \[[@B38]\]. The simplicity of the Arteriograph, its operator-independence and measurement using a single brachial cuff, makes it conducive for normal clinical care in low resource region like sub-Saharan Africa. However, the findings of this study indicate that PWVao measured by Arteriograph can covary with BP making aortic stiffness susceptible to white collar effect. The Vasera, which measures arterial stiffness using a novel stiffness index, CAVI, was found to be less dependent on blood pressure in this study. CAVI has been shown to be a useful tool to screen persons with moderate to advanced levels of arteriosclerosis. Horinaka et al. \[[@B39]\] reported that CAVI was strongly associated with plaque burden measure by coronary intravascular ultrasound in the left main coronary artery of patients with coronary artery disease. Mineoka et al. \[[@B40]\] also showed that CAVI correlated with coronary artery calcification, implying that CAVI could be an evaluation index for macrovascular complication of diabetes. In this study, CAVI was found to be associated with most of the traditional cardiovascular risk factors, raising the possibility that CAVI might predict cardiovascular outcomes in population of African ancestry. However, further longitudinal studies are required to investigate this claim.

The haPWV, from which CAVI was derived, measures the stiffness in central (descending aorta) and muscular arteries. The findings of this study show that haPWV was associated with most CVD risk factor. Diabetes affects the stiffness of central elastic arteries more drastically than peripheral muscular arteries \[[@B6]\], making measurement of peripheral arterial stiffness alone less informative in diabetes patients. Unlike stiffness in central elastic arteries (heart-femoral PWV), peripheral stiffness, measured as femoral-ankle PWV, was associated with neither ischaemic heart disease \[[@B41]\] nor chronic kidney disease \[[@B42]\] in T2DM patients. haPWV is rarely reported in literature, but its analogous stiffness index, the brachial-ankle PWV (baPWV), has been widely studied. baPWV is associated with CVD risk factors \[[@B43]\], and, in one study, baPWV was found to be better associated with left ventricular mass, diastolic functions, and other indices of arterial functions better than carotid-femoral PWV \[[@B44]\]. This may imply that peripheral arterial stiffness adds more information of central elastic arterial stiffness in predicting arterial function and target-organ damage.

5. Limitations of the Study {#sec5}
===========================

The study was a case-control design with subjects recruited from a specialized clinical facility and nondiabetes controls were conveniently sampled from the general population. Hence, we cannot infer causality from the data and the conclusion cannot be generalized to the entire Ghanaian population. In addition, humoural biomarkers that underline the pathophysiological mechanisms of arterial stiffness were not assayed. Of particular importance is hypogonadism, assessed as low plasma testosterone levels, which has been associated with cardiovascular risk factors such as obesity, insulin resistance, metabolic syndrome, and high BP; all these conditions are associated with increased arterial stiffness \[[@B45]\]. Testosterone has also been shown to decrease the intrinsic tone of vascular smooth muscle in chemically induced diabetes animal models by downregulating the activity of the RhoA/Rho kinase involved in calcium signalling in vascular smooth muscle cells \[[@B46]\]. This may partially explain the observation in male diabetes patients, in which PWV was inversely associated with plasma testosterone and dehydroepiandrosterone sulphate levels. Indeed, a recent study involving adult men without any CVDs reported that low testosterone was associated with aortic stiffness \[[@B47]\].

6. Conclusion {#sec6}
=============

In summary, this study has shown that arterial stiffness, measured as PWVao and CAVI, is elevated in T2DM patients in the absence of obesity and hypertension. This increase in arterial stiffness was not accompanied with significant elevation of central haemodynamic pressure indices. Hence, in nonhypertensive T2DM patients, medication reducing arterial stiffness such as angiotensin conversion enzyme inhibitors, angiotensin receptor inhibitors, and calcium channel blockers may be beneficial \[[@B48]\]. Also, possibility of reducing arterial stiffness by screening and treating hypogonadism in T2DM patients may be investigated in future studies \[[@B49]\].
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###### 

Clinical characteristics of study subjects.

                                   T2DM patients (*n* = 96)   Controls (*n* = 70)   *p*
  -------------------------------- -------------------------- --------------------- -----------
  Age                              51.5 ± 11.7                50.6 ± 11.1           0.733
  Gender (males/females)           40/56                      30/40                 0.234
  Alcohol intake (%)               18.2                       22.1                  0.078
  Previous smokers (%)             14.3                       7.8                   0.428
  Duration of diabetes (years)     2.6 ± 1.8                  ---                   ---
  *FPG (mmol/L)*                   *8.4 ± 3*                  *5 ± 1*               *\<0.001*
  2 h PPG (mmol/L)                 ---                        6.2 ± 2.2             ---
  HbA1c (%)                        **8.3  ±  1.4**            **5.2  ±  0.9**       \<0.001
  *Total cholesterol (mmol/L)*     *4.1 ± 4.2*                *5.3 ± 1.4*           *\<0.001*
  Fasting triglycerides (mmol/L)   1 ± 0.5                    1.1 ± 0.5             0.310
  HDL (mmol/L)                     0.8 ± 0.7                  0.8 ± 0.5             0.793
  *LDL (mmol/L)*                   *4.1 ± 1.3*                *2.8 ± 1.3*           *\<0.001*
  BMI (kg/m^2^)                    26.5 ± 4.4                 28.5 ± 5.3            0.085
  Body fat (%)                     30.4 ± 10.1                33.3 ± 13.7           0.305
  Visceral fat (%)                 11.1 ± 5.1                 9.9 ± 3.1             0.165
  Waist circumference (cm)         93.9 ± 10.3                93.5 ± 17.5           0.897
  Waist-hip ratio                  0.91 ± 0.07                0.92 ± 0.19           0.797
  Arteriograph measurements                                                          
    *PWVao (m/s)*                  *8.3 ± 1*                  *7.8 ± 1.3*           *0.004*
   Aortic systolic BP (mmHg)       116 ± 12                   119 ± 11              0.195
   Aortic pulse BP (mmHg)          39 ± 13                    43 ± 14               0.201
   Augmentation index (%)          20 ± 12                    25 ± 13               0.138
   Systolic BP (mmHg)              124 ± 9                    124 ± 10              0.748
   Diastolic BP (mmHg)             74 ± 7                     74 ± 9                0.977
   Pulse BP (mmHg)                 50 ± 7                     50 ± 8                0.640
   Mean BP (mmHg)                  116 ± 10                   115 ± 11              0.939
    *Heart rate (bpm)*             *74 ± 10*                  *65 ± 11*             *0.001*
  Vasera measurements                                                                
   Systolic BP                     130 ± 11                   133 ± 32              0.613
    *Diastolic BP*                 *82 ± 8*                   *88 ± 12*             *0.039*
    *Pulse BP*                     *48 ± 9*                   *50 ± 12*             *0.04*
   Mean BP                         98 ± 8                     104 ± 14              0.402
    *Heart rate*                   *73 ± 10*                  *65 ± 12*             *0.001*
    *CAVI*                         *7.9 ± 1.2*                *6.9 ± 0.7*           *0.021*
   haPWV (m/s)                     7.4 ± 0.8                  7 ± 0.8               0.263

BMI: body mass index; BP: blood pressure; HR: heart rate; PWVao: aortic pulse wave velocity; AIx: augmentation index; CAVI: cardioankle vascular index; haPWV: heart-ankle PWV.

###### 

Multiple regression analysis between patients\' characteristics versus PWVao and CAVI.

                           PWVao      CAVI                      
  ------------------------ ---------- ------------- ----------- -------------
  All subjects                                                   
   Diabetes status         **0.22**   **0.02**      **0.21**    **0.029**
   Age                     **0.36**   **\<0.001**   **0.38**    **\<0.001**
   Gender                  **0.48**   **\<0.001**   0.04        0.692
   log BMI                 0.13       0.185         **0.20**    **0.033**
   log WHR                 0.06       0.538         0.17        0.067
   log height              0.16       0.092         0.05        0.577
   log systolic BP         **0.21**   **0.005**     −0.08       0.309
   log heart rate          0.05       0.549         **0.18**    **0.026**
   Previous smoking        **0.25**   **0.001**     **0.20**    **0.008**
   Alcohol intake          0.01       0.894         0.02        0.759
   HbA1c                   0.01       0.922         **0.24**    **0.007**
   log total cholesterol   −0.04      0.659         **0.20**    **0.014**
   log triglycerides       0.01       0.985         0.03        0.76
   log HDL                 0.01       0.974         **−0.19**   **0.014**
  T2DM patients                                                  
   Age                     **0.25**   **0.024**     **2.82**    **0.006**
   Diabetes duration       **0.27**   **0.01**      **4.29**    **\<0.001**
   Gender                  **0.37**   **0.006**     −1.46       0.148
   log BMI                 0.16       0.216         0.31        0.759
   log WHR                 0.06       0.62          1.16        0.251
   log height              −0.01      0.947         −0.84       0.404
   log systolic BP         **0.34**   **0.003**     1.37        0.176
   log heart rate          0.04       0.7           1.52        0.134
   Previous smoking        **0.23**   **0.027**     0.66        0.512
   Alcohol intake          **0.20**   **0.043**     1.44        0.155
   HbA1c                   −0.10      0.424         1.92        0.058
   log total cholesterol   −0.01      0.906         **3.15**    **0.002**
   log triglycerides       −0.02      0.888         −0.74       0.464
   log HDL                 0.01       0.902         1.48        0.144
  Controls                                                       
   Age                     **0.42**   **0.012**     **2.98**    **0.005**
   Gender                  **0.74**   **0.006**     0.12        0.906
   log BMI                 0.37       0.099         1.70        0.098
   log WHR                 0.16       0.423         **2.50**    **0.017**
   log height              0.34       0.074         0.92        0.363
   log systolic BP         0.03       0.886         **2.60**    **0.013**
   log heart rate          0.28       0.217         **2.15**    **0.038**
   Previous smoking        0.19       0.21          **4.10**    **\<0.001**
   Alcohol intake          −0.16      0.295         0.57        0.575
   HbA1c                   0.30       0.109         1.18        0.244
   log total cholesterol   0.08       0.625         1.30        0.201
   log triglycerides       −0.11      0.591         1.05        0.302
   log HDL                 −0.08      0.59          **−1.43**   **0.001**

###### 

Multiple regression analysis between patients\' characteristics versus haPWV and augmentation index.

                           haPWV       AIx                       
  ------------------------ ----------- ------------- ----------- -------------
  All subjects                                                    
   Diabetes status         −0.11       0.246         **0.21**    **0.037**
   Age                     **0.42**    **\<0.001**   **0.14**    **0.018**
   Gender                  **−0.22**   **0.03**      **0.20**    **0.017**
   log BMI                 **0.29**    **0.003**     0.01        0.94
   log WHR                 **0.19**    **0.044**     −0.01       0.911
   log height              −0.09       0.315         **−0.44**   **\<0.001**
   log systolic BP         0.09        0.217         **0.14**    **0.018**
   log heart rate          **0.20**    **0.014**     **−0.51**   **\<0.001**
   Previous smoking        0.14        0.059         −0.03       0.581
   Alcohol intake          **0.27**    **\<0.001**   0.04        0.439
   HbA1c                   **0.26**    **0.004**     **0.16**    **0.026**
   log total cholesterol   **0.17**    **0.039**     0.07        0.282
   log triglycerides       0.16        0.057         0.04        0.504
   log HDL                 **−0.28**   **\<0.001**   0.04        0.469
  T2DM patients                                                   
   Age                     **0.26**    **0.002**     0.03        0.717
   Diabetes duration       **0.45**    **\<0.001**   −0.02       0.787
   Gender                  **−0.25**   **0.02**      0.12        0.252
   BMI                     0.12        0.274         0.05        0.609
   WHR                     **0.28**    **0.004**     −0.01       0.909
   Height                  −0.16       0.092         **−0.5**    **\<0.001**
   Systolic BP             **0.41**    **\<0.001**   **0.2**     **0.031**
   Heart rate              **0.17**    **0.037**     **−0.61**   **\<0.001**
   Previous smoking        0.11        0.191         −0.05       0.555
   Alcohol intake          **0.17**    **0.026**     0.09        0.262
   HbA1c                   **0.2**     **0.017**     **0.29**    **0.001**
   log total cholesterol   0.12        0.153         0.11        0.212
   log triglycerides       0.04        0.71          0.08        0.364
   log HDL                 0.16        0.064         **0.17**    **0.04**
  Controls                                                        
   Age                     **0.29**    **0.007**     **0.46**    **\<0.001**
   Gender                  −0.09       0.603         0.17        0.304
   BMI                     0.31        0.052         0.10        0.453
   WHR                     0.24        0.111         **0.27**    **0.037**
   Height                  0.06        0.623         **−0.58**   **\<0.001**
   Systolic BP             −0.12       0.231         −0.05       0.678
   Heart rate              0.01        0.93          −0.01       0.936
   Previous smoking        −0.06       0.622         −0.13       0.158
   Alcohol intake          **0.36**    **0.001**     **−0.19**   **0.044**
   HbA1c                   **0.30**    **0.009**     0.14        0.242
   log total cholesterol   **0.28**    **0.007**     0.18        0.077
   log triglycerides       0.01        0.996         −0.02       0.846
   log HDL                 **−0.35**   **0.003**     **−0.20**   **0.031**

[^1]: Academic Editor: Mario Maggi
